Eaton Vance Tax-Advantaged Dividend Income Fund (EVT)
| Market Value | 1.95B |
| Revenue (ttm) | 67.32M -3.0% |
| Net Income | 186.04M -62.3% |
| EPS | 2.50 -62.3% |
| Shares Out | 74.54M |
| PE Ratio | 10.45 |
| Forward PE | n/a |
| Dividend | $1.98 (7.57%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 104,714 |
| Open | 26.14 |
| Previous Close | 26.09 |
| Day's Range | 25.80 - 26.19 |
| 52-Week Range | 21.87 - 26.65 |
| Beta | 1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EVT
Eaton Vance Tax-Advantaged Dividend Income Fund is a closed-ended equity mutual fund launched and managed by Eaton Vance Management. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating across the diversified sectors. The fund primarily invests in dividend paying value stocks of companies that qualify for favorable federal income tax treatment. It benchmarks the performance of its portfolio against the Russell 1000 Value Index. Eaton Vance Tax-Advantaged Dividend Income Fund was formed ... [Read more]
Financial Performance
In fiscal year 2025, EVT's revenue was $67.32 million, a decrease of -3.00% compared to the previous year's $69.40 million. Earnings were $186.04 million, a decrease of -62.33%.
Financial StatementsNews
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q4 2025
Delivered strong Q4 growth and high-end full-year results in 2025, driven by Just - Evotec Biologics and strategic partnerships. Horizon transformation and commercial reorganization set the stage for margin expansion and sustainable growth, with 2026 as a transition year.
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: Status update
Horizon transformation will streamline operations, reduce costs, and focus on scientific and commercial excellence, targeting EUR 75 million in savings by 2027 and a 20% EBITDA margin by 2028. 2026 is a transition year, with market recovery and operational improvements expected to drive growth from 2027.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q3 2025
Group revenues declined 7% year-over-year to EUR 535.1 million, driven by a 12% drop in DNPD, while biologics grew 11% and secured a major Sandoz deal worth over $650 million. Cost reduction initiatives are ahead of plan, and the company confirmed 2025 guidance with improved free cash flow and a shift to a higher-margin, asset-light model.
5 High Yield CEFs With Steep Discounts Right Now
Closed-end funds (CEFs) are the last bargains left on the board. CEFs are often confused with mutual funds and ETFs, but they are different because they often trade at discounts to their net asset val...
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q2 2025
H1 2025 saw group revenues decline 5% year-over-year, with D&PD down 11% and JEB up 16%. Strategic focus shifted to an asset-light, higher-margin model, highlighted by the planned €300M sale of J.POD Toulouse to Sandoz. Full-year guidance and midterm growth targets remain on track.
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: Health Care Conference
The presentation outlined a renewed strategic focus on innovation, operational excellence, and capital efficiency, with a shift toward integrated, success-sharing partnerships. Despite near-term market challenges, robust technology platforms and a strong pipeline position the company for above-market growth and improved margins by 2028.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q1 2025
Q1 2025 revenues declined 4% year-over-year to EUR 200 million, with shared R&D underperforming but Just Evotec Biologics exceeding expectations. Cost-saving measures are on track, guidance for 2025 is reaffirmed, and strong technology-driven collaborations continue to drive future growth.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q4 2024
2024 saw modest revenue growth and strong Q4 results, with Just - Evotec Biologics driving expansion and cost-saving measures improving profitability. 2025 guidance anticipates 5%-10% revenue growth, continued operational discipline, and further investment in high-value, tech-driven segments.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q3 2024
2024 saw flat revenues overall, with strong growth in Biologics offsetting softness in Shared R&D. Cost-saving initiatives and new strategic partnerships are driving improved margins and liquidity, with a substantial Q4 profit uplift expected. Guidance for 2024 is confirmed.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q2 2024
H1 2024 saw modest revenue growth driven by Just – Evotec Biologics, but profitability was impacted by high fixed costs and a challenging market, prompting a strategic reset and cost-saving measures. Full-year guidance was revised downward, with recovery expected in 2025.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q1 2024
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q4 2023
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: CMD 2023
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q3 2023
This Monthly-Paying Mini-Portfolio Delivers 11.1% Each Year
It's a great time to be an income investor. We have yields averaging 11.1% staring us in the face.
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q2 2023
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: Guidance
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: ESG Update
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: Partnership
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q4 2022
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q3 2022
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q2 2022
Eaton Vance Tax-Advantaged Dividend Income Fund Transcript: Partnership
Eaton Vance Tax-Advantaged Dividend Income Fund Earnings Call Transcript: Q1 2022
22 Dividend Funds Yielding Up To 36.5%
With 2022 likely to be a wild ride, we income investors are going to lean on two key advantages.